Gilead Sciences is turning to gene editing in its effort to develop a cure for hepatitis B virus infections-DNA-cutting enzymes that would eliminate the virus in the body, something current hep B drugs can’t do.
Foster City, CA-based Gilead (NASDAQ: GILD) is partnering with Precision Biosciences, a company that has used its proprietary gene-editing platform to develop products for both agriculture and human health. No upfront payments were disclosed, but if the alliance results in commercialized drugs, Durham, NC-based Precision stands to gain up to $445 million in milestone payments and royalties. Under the agreement, Gilead will fund the research… Read more »
UNDERWRITERS AND PARTNERS